Genetic characterisation of influenza B viruses detected in Singapore, 2004 to 2009

BMC Research Notes

Boon-Huan Tan²  Richard J Sugrue¹  Muhammad Raihan Jumat¹ 

[1] Division of Molecular and Cell Biology, School of Biological Sciences, Nanyang Technological University, Singapore 637551, Republic of Singapore;Saw Swee Hock School of Public Health, Faculty of Medicine, National University Singapore, Singapore 117549, Republic of Singapore

关键词: Vaccine efficiency;    Circulating lineage;    Singapore;    Surveillance;    Viral evolution;    Phylogenetic analysis;    Influenza B;   

Others  :  1118088
DOI  :  10.1186/1756-0500-7-863

 received in 2014-08-12, accepted in 2014-11-21,  发布年份 2014

【 摘 要 】

Background

Influenza B viruses are classified into two main lineages: Yamagata-like and Victoria-like, which differ antigenically and phylogenetically. To understand the evolution of influenza B viruses in South East Asia as well as to determine the vaccine efficacy, we genetically characterised gene segments 4, 6 and 8 from non-tissue culture adapted influenza B viruses detected in Singapore from 2004 to 2009.

Methods

vRNA were extracted from the nasopharyngeal swabs or nasal washes of SAF servicemen displaying febrile and respiratory symptoms, and subjected to PCR assay to test for the presence of influenza B virus. The PCR-positive specimens were next subjected to sequencing of the full gene segments 4 (HA), 6 (NA/NB) and 8 (NS1/NEP). The nucleotide sequences were aligned together with that of other specimens isolated from South East Asia as well as the vaccine strains. Phylogenetic trees of each gene segment were constructed and the amino acid alignments were analysed.

Results

A majority of the Singaporean specimens analysed in this study, from 2004–2009, had gene segment 4 from the Victoria-like lineage and gene segment 6 from Yamagata-like lineage. Some of these specimens had both gene segments from the Yamagata lineage and this resulted in several vaccine mismatches. Gene segment 8 from majority of these specimens clustered separately from both the Yamagata and Victoria strains. The HA protein of most of the Singaporean specimens isolated post 2000 contained a glycosylation site at position 211, which was not dominant prior to 2000. No amino acid substitution conferring drug-resistance was found in either the HA or NA proteins.

Conclusions

The presence of both lineages co-circulating post 2000, suggests that a trivalent vaccine is not enough to confer immunity to the general public, strongly endorsing the inclusion of both lineages in the vaccine. Several amino acid substitutions were observed, prompting in depth functional analyses.

【 授权许可】

   
2014 Jumat et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Osterhaus AD, Rimmelzwaan GF, Martina BE, Bestebroer TM, Fouchier RA: Influenza B Virus in Seals. Science 2000, 288:1051-1053.
• [2]Sridharan H, Zhao C, Krug RM: Species specificity of the NS1 protein of influenza B virus: It binds only human and non-human primate ubiquitin-like ISG15 proteins. J Biol Chem 2010, 285(11):7852-7856.
• [3]Murphy BR, Webster RG: Virology, B.N. Fields et al. 1990.
• [4]Nerome R, Hiromoto Y, Sugita S, Tanabe N, Ishida M, Matsumoto M, Lindstrom SE, Takahashi T, Nerome K: Evolutionary characteristics of influenza B virus since its first isolation in 1940: dynamic circulation of deletion and insertion mechanism. Arch Virol 1998, 143:1569-1583.
• [5]Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K: Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990, 175:59-68.
• [6]Kanegae Y, Sugita S, Endo A, Ishida M, Senya S, Osako K, Nerome K, Oya A: Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season. J Virol 1990, 64:2860-2865.
• [7]Chi XS, Bolar TV, Zhao P, Rappaport R, Cheng S-M: Cocirculation and evolution of two lineages of influenza B viruses in Europe and Israel in the 2001–2002 season. J Clin Microbiol 2003, 41:5770-5773.
• [8]Chi XS, Hu A, Bolar TV, Al-Rimawi W, Zhao P, Tam JS, Rappaport R, Cheng S-M: Detection and characterization of new influenza B virus variants in 2002. J Clin Microbiol 2005, 43:2345-2349.
• [9]WHO: Recommended composition of influenza virus vaccines for use in the 2009–2010 northern hemisphere influenza season. 2009.
• [10]Derlet RW: Influenza. eMedicine Infectious Diseases 2010.
• [11]Wright P, Neumann G, Kawaoka Y: Orthomyxoviruses. Fields Virology 5th edition. 2006, 1691-1740.
• [12]Kim YH, Kim HS, Cho SH, Seo SH: Influenza B virus causes milder pathogenesis and weaker inflammatory responses in ferrets than influenza A virus. Viral Immunol 2009, 22:423-430.
• [13]William BB, James PL, Stanley MM: Severe illness with influenza B. Am J Med 1980, 68:181-189.
• [14]Wright PF, Bryant JD, Karzon DT: Comparison of influenza B/Hong Kong virus infections among infants, children, and young adults. J Infect Dis 1980, 141:430-435.
• [15]Michael KF, John CP, Kevin EB, Robert J, Pamela KH: Epidemic influenza myopathy in Cincinnati in 1977. J Pediatr 1980, 96:545-551.
• [16]Wu C-T, Hsia S-H, Huang J-L: Influenza B-associated rhabdomyolysis in Taiwanese children. Acta Pædiatrica 2010, 99:1701-1704.
• [17]GISRS WHO: Global circulation of influenza viruses. 2013. http://gamapserver.who.int/gareports/Default.aspx?ReportNo=6 webcite
• [18]GISRS WHO: Influenza Laboratory Surveillance Information by GISRS. Influenza Transmission zone: South East Asia. 2013. http://gamapserver.who.int/gareports/Default.aspx?ReportNo=4&ITZRegion= webcite
• [19]GISRS WHO: Percentage of respiratory specimens that tested positive for influenza by influenza transmission zone. Status as of week 51 16–22 December 2012. 2013. http://www.who.int/influenza/surveillance_monitoring/updates/2013_01_07_influenza_update_176_week_51_main.jpg webcite
• [20]Fields BN, Knipe DM, Howley PM: Fields' virology. 5th edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007.
• [21]Earp L, Delos S, Park H, White J: The many mechanisms of viral membrane fusion proteins. Curr Top Microbiol Immunol 2005, 25-66.
• [22]Palese P, Compans RW: Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976, 33:159-163.
• [23]Palese P, Tobita K, Ueda M, Compans RW: Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974, 61:397-410.
• [24]Quan F-S, Kim M-C, Lee B-J, Song J-M, Compans RW, Kang S-M: Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology 2012, 430:127-135.
• [25]McCullers JA, Saito T, Iverson AR: Multiple genotypes of influenza B virus circulated between 1979 and 2003. J Virol 2004, 78:12817-12828.
• [26]McCullers JA, Wang GC, He S, Webster RG: Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature. J Virol 1999, 73:7343-7348.
• [27]Doraisingham: Influenza surveillance in Singapore: 1972–86. Bull World Health Organisat 1988, 66:7.
• [28]Chow SM, Ai Ee L, Suok Kai C: Influenza-associated deaths in tropical Singapore. Emerg Infect Dis 2006, 12:8.
• [29]Lee VJ, Yap J, Ong JBS, Chan K-P, Lin RTP, Chan SP, Goh KT, Leo Y-S, Chen MIC: Influenza excess mortality from 1950–2000 in tropical Singapore. PLoS One 2009, 4:e8096.
• [30]Seah SG-K, Lim EA-S, Kok-Yong S, Liaw JC-W, Lee V, Kammerer P, Metzgar D, Russell KL, Tan B-H: Viral agents responsible for febrile respiratory illnesses among military recruits training in tropical Singapore. 2010. In Press, Corrected Proof
• [31]Communicable Diseases Division MS: Weekly infectious disease bulletin, epidemiological week 30, 22–28 June 2012. CDC, Ministry of Health, Singapore 2012., 9(30) https://www.moh.gov.sg/content/dam/moh_web/Statistics/Infectious_Diseases_Bulletin/2012/July/2012_week_30.pdf webcite
• [32]MOH S: Weekly infectious disease bulletin. CDC Ministry of Health, Singapore 2014 11(11) https://www.moh.gov.sg/content/dam/moh_web/Statistics/Infectious_Diseases_Bulletin/2014/March/2014_week_11.pdf webcite
• [33]Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y: Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007, 297:1435-1442.
• [34]Ng TP, Pwee KH, Niti M, Goh LG: Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singapore 2002, 31:182-188.
• [35]Luo C, Morishita T, Satou K, Tateno Y, Nakajima K, Nobusawa E: Evolutionary pattern of influenza B viruses based on the HA and NS genes during 1940 to 1999: origin of the NS genes after 1997. Arch Virol 1999, 144:1881-1891.
• [36]Abed Y, Coulthart MB, Li Y, Boivin G: Evolution of surface and nonstructural-1 genes of influenza B viruses isolated in the province of Québec, Canada, during the 1998–2001 period. Virus Genes 2003, 27:125-135.
• [37]Matsuzaki Y, Sugawara K, Takashita E, Muraki Y, Hongo S, Katsushima N, Mizuta K, Nishimura H: Genetic diversity of influenza B virus: the frequent reassortment and cocirculation of the genetically distinct reassortant viruses in a community. J Med Virol 2004, 74:132-140.
• [38]Nakagawa N, Suzuoki J, Kubota R, Kobatake S, Okuno Y: Discovery of the neutralizing epitope common to influenza B virus Victoria group isolates in Japan. J Clin Microbiol 2006, 44:1564-1566.
• [39]Nakagawa N, Kubota R, Okuno Y: Variation of the conserved neutralizing epitope in influenza B virus Victoria group isolates in Japan. J Clin Microbiol 2005, 43:4212-4214.
• [40]Nakagawa N, Kubota R, Maeda A, Okuno Y: Influenza B virus Victoria group with a new glycosylation site was epidemic in Japan in the 2002–2003 season. J Clin Microbiol 2004, 42:3295-3297.
• [41]Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin Ö, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Pieris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH: Highly conserved protective epitopes on influenza B viruses. Science 2012, 337:1343-1348.
• [42]Burmeister WP, Ruigrok RW, Cusack S: The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J 1992, 11:49-56.
• [43]Fischer WB, Pitkeathly M, Sansom MSP: Amantadine blocks channel activity of the transmembrane segment of the NB protein from influenza B. Eur Biophys J 2001, 30:416-420.
• [44]Fischer WB, Pitkeathly M, Wallace BA, Forrest LR, Smith GR, Sansom MSP: Transmembrane peptide NB of influenza B: a simulation, structure, and conductance study†. Biochemistry 2000, 39:12708-12716.
• [45]Betakova T, Nermut MV, Hay AJ: The NB protein is an integral component of the membrane of influenza B virus. J Gen Virol 1996, 77:2689-2694.
• [46]Hatta M, Kawaoka Y: The NB protein of influenza B virus is not necessary for virus replication in vitro. J Virol 2003, 77:6050-6054.
• [47]Schneider J, Dauber B, Melen K, Julkunen I, Wolff T: Analysis of influenza B virus NS1 protein trafficking reveals a novel interaction with nuclear speckle domains. J Virol 2009, 83:701-711.
• [48]Yuan W, Krug RM: Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J 2001, 20:362-371.
• [49]Guan R, Ma L-C, Leonard PG, Amer BR, Sridharan H, Zhao C, Krug RM, Montelione GT: Structural basis for the sequence-specific recognition of human ISG15 by the NS1 protein of influenza B virus. Proc Natl Acad Sci 2011, 108(33):13468-13473.
• [50]CDC: Update: influenza activity-United States and world-wide, May-September 2001. MMWR Morb Mortal Wkly Rep 2001, 50:4.
• [51]Nakagawa KR, Maeda A, Nakagawa T, Okuno Y: Heterogeneity of influenza B virus strains in one epidemic season differentiated by monoclonal antibodies and nucleotide sequences. J Clin Microbiol 2000, 38:3.
• [52]WHO: Recommended composition of influenza virus vaccines for use in the 1999–2000 season. Wkly Epidemiol Rec 1999, 7:5.
• [53]WHO: Recommended COmposition of influenza virus vaccines for use in the 2002–2003 season. Wkly Epidemiol Rec 2002, 77:5.
• [54]Barr IG, Komadina N, Durrant C, Sjogren H, Hurt AC, Shaw RP: Circulation and antigenic drift in human influenza B viruses in SE Asia and Oceania since 2000. Commun Dis Intell 2006, 30:350-357.
• [55]Levandowski RA, Regnery HL, Staton E, Burgess BG, Williams MS, Groothuis JR: Antibody responses to influenza B viruses in immunologically unprimed children. Pediatrics 1991, 88:1031-1036.
• [56]Rota PA, Hemphill ML, Whistler T, Regnery HL, Kendal AP: Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. J Gen Virol 1992, 73:2737-2742.
• [57]CDC: Influenza activity--United States and worldwide, 2007–08 season. MMWR Morb Mortal Wkly Rep 2008, 57:692-697.
• [58]Belshe RB: The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010, 28(Supplement 4):D45-D53.
• [59]Reed C, Meltzer MI, Finelli L, Fiore A: Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30(11):1993-1998.
• [60]Ambrose CS, Levin MJ: The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunotherapeutics 2012, 8:81-88.
• [61]Schulze IT: Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J Infect Dis 1997, 176:S24-S28.
• [62]Pica N, Palese P: Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013, 64:189-202.
• [63]Gubareva LV: Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004, 103:199-203.
• [64]Gubareva Larisa V, Matrosovich Mikhail N, Brenner Malcolm K, Bethell Richard C, Webster Robert G: Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998, 178:1257-1262.
• [65]Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Hornback WJ, Munroe JE, Laver WG: Molecular basis for the resistance of influenza viruses to 4-Guanidino-Neu5Ac2en. Virology 1995, 214:642-646.
• [66]Barnett JM, Cadman A, Burrell FM, Madar SH, Lewis AP, Tisdale M, Bethell R: In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 1999, 265:286-295.
• [67]McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, Hayden F, Zambon M: Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003, 47:2264-2272.
• [68]McKimm-Breschkin JL: Resistance of influenza viruses to neuraminidase inhibitors – a review. Antiviral Res 2000, 47:1-17.
• [69]Cheam AL, Barr I, Mosse J, Hampson A, Hurt A: Characterisation of an influenza B variant selected with the neuraminidase inhibitor zanamivir. Int Congr Ser 2004, 1263:122-125.
• [70]Cheam AL, Barr IG, Hampson AW, Mosse J, Hurt AC: In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Antiviral Res 2004, 63:177-181.
• [71]Mishin VP, Hayden FG, Gubareva LV: Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005, 49:4515-4520.
• [72]Hurt AC, Iannello P, Jachno K, Komadina N, Hampson AW, Barr IG, McKimm-Breschkin JL: Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother 2006, 50:1872-1874.
• [73]Zou S: A practical approach to genetic screening for influenza virus variants. J Clin Microbiol 1997, 35:2623-2627.
• [74]Hoffmann E, Mahmood K, Yang C-F, Webster RG, Greenberg HB, Kemble G: Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci U S A 2002, 99:11411-11416.
• [75]Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994, 22:4673-4680.
• [76]WHO: Recommended composition of influenza virus vaccines for use in the 2004 influenza season. Wkly Epidemiol Rec 2003, 78:375-379.
• [77]WHO: Recommended composition of influenza virus vaccines for use in the 2004–2005 influenza season. Wkly Epidemiol Rec 2004, 79:88-92.
• [78]WHO: Recommended composition of influenza virus vaccines for use in the 2005 influenza season. Wkly Epidemiol Rec 2004, 79:369-373.
• [79]WHO: Recommended composition of influenza virus vaccines for use in the 2005–2006 influenza season. Wkly Epidemiol Rec 2005, 80:71-75.
• [80]WHO: Recommended composition of influenza virus vaccines for use in the 2006 influenza season. Wkly Epidemiol Rec 2005, 80:342-347.
• [81]WHO: Recommended composition of influenza virus vaccines for use in the 2006–2007 influenza season. Wkly Epidemiol Rec 2006, 81:82-86.
• [82]WHO: Recommended composition of the 2006/07 influenza vaccine. Euro Surveill 2006, 11:E060330-060332.
• [83]WHO: Recommended composition of influenza virus vaccines for use in the 2007 influenza season. Wkly Epidemiol Rec 2006, 81:390-395.
• [84]WHO: Recommended composition of influenza virus vaccines for use in the 2008 influenza season. Wkly Epidemiol Rec 2007, 82:351-356.
• [85]WHO: Recommended composition of influenza virus vaccines for use in the 2007–2008 influenza season. Wkly Epidemiol Rec 2007, 82:69-74.
• [86]WHO: Recommended composition of influenza virus vaccines for use in the 2008–2009 influenza season. Wkly Epidemiol Rec 2008, 83:81-87.
• [87]WHO: Recommended composition of influenza vaccines for use in the 2012 southern hemisphere influenza season. Wkly Epidemiol Rec 2011, 86:457-468.
• [88]WHO: Recommended composition of influenza virus vaccines for use in the 2012–2013 northern hemisphere influenza season. Wkly Epidemiol Rec 2012, 87:83-95.
• [89]Tsai H-P, Wang H-C, Kiang D, Huang S-W, Kuo P-H, Liu C-C, Su I-J, Wang J-R: Increasing appearance of reassortant influenza B virus in Taiwan from 2002 to 2005. J Clin Microbiol 2006, 44:2705-2713.
• [90]Krafft AE, Russell KL, Hawksworth AW, McCall S, Irvine M, Daum LT, Connoly JL, Reid AH, Gaydos JC, Taubenberger JK: Evaluation of PCR testing of ethanol-fixed nasal swab specimens as an augmented surveillance strategy for influenza virus and adenovirus identification. J Clin Microbiol 2005, 43:1768-1775.